Form 4: Halozyme Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Dannielle Appelhans, a Director of Halozyme Therapeutics, Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Grant/award: acquired 1,161 Restricted Stock Units on September 1, 2026; holds 1,161 after (Direct).
- Grant/award: acquired 1,778 Option to Purchase Common Stock on September 1, 2026; holds 1,778 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dannielle Appelhans — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Restricted Stock Units | 1,161 | — | — | 1,161 |
| 2026-09-01 | Grant/award | Option to Purchase Common Stock | 1,778 | — | — | 1,778 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (1,161 shares) |
| 2026-09-01 | Grant/award (1,778 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., neutral, Dannielle Appelhans
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.